Actuary the average premium for both drugs offered only plans and drug coverage from private Medicare Advantage plans. Monthly premiums for drug-only plans are expected to be from $ 27 this year, increased to $ 31 next year, and the premiums for MA drug plans by $ by $ 18 per month to $ 21 to $ 21 next year (CQ HealthBeat, According CMS, the increase rising drug costs, higher forecasts for catastrophic drug coverage and the end of a demonstration project..

Research has opened the door to identify the relevant gene in the pathogenesis of hepatocellular carcinoma, because it non-tumorous non-tumorous liver, as well as the initiation of the investigation of molecular techniques for the determination , which arises a risk for the development of . . added that added that bring the possibility of individualized therapy for hepatocellular carcinoma one step closer. these results.. In an editorial on the report of the results, Morris Sherman, of the University of Toronto, agreed that the added new insights into understanding the development of liver cancer.In January 2006, TyRx announced, precise product specifications. Developed into an exclusive license by Baylor College of Medicine and The University of Texas MD Anderson Cancer Center to use three product patents and its associated technologies of the two bodies listed on the development of innovative cardio and surgery medical equipment developing to address the problem of postoperative nosocomial infection.

TyRx pharmaceuticals.. On TyRx Pharma – has TyRx organized in 1998 to commercialize a new combinatorial chemistry -based biomaterials technology solely of Rutgers, The State University of New Jersey licenses, substances like substances such as tyrosine biologically medical quality built polymers. On proprietary polymerisation TyRx efficiency updated on tailored polymers to meet precise product specifications. TyRx has making available their abilities in a wide range of combination products.